ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

CAUSES, CLINICAL FEATURES, DIAGNOSIS, CLINICAL PRESENTATION, BIOCHEMICAL TESTING, IMAGING STUDIES, OTHER DIAGNOSTIC TOOLS, DIFFERENTIAL DIAGNOSIS AND TREATMENT OF ACROMEGALY.

Vikunta Rao. V¹, Muralinath E.¹, Manjari P.¹, Sravani Pragna K.¹ KALYAN C.¹ Guru Prasad M², Venkat Navven. A³, Sravani. K.⁴, Sony Sharlet. E ⁵ ¹College of Veterinary Science, Proddatur, Andhra Pradesh, India. ²Vaishnavi microbial Phama pvt.ltd, Hyderabad, India ³Technical Sales Officer, Vijayawada, Andhra Pradesh, India

⁴Veterinary Officer, Nuzivedu, Andhra Pradesh, India ⁵Veterinary college, Tirupati, Andhra Pradesh, India

ABSTRACT:-

Acromegaly is a rare endocrine disorder occurred by an over production of growth hormone. Causes of acromegaly include benign tumor of pituitary gland, over production of growth hormone as well as genetic predisposition. Clinical features of acromegaly are acral enlargement, prognatism, kyphosis, soft tissue as well as facial chanjes, hyper glycemia, hypertension, hypogonadism, thyroid dysfunction and cardiomyopathy. Diagnosis is based on MRI and CT scan. Treatment is dependent on somatostatin analogs, dopamine agonists, GH receptor antagonists.

KEY WORDS: Pituitary tumor, benign tumor of the pituitary glands, over production of GH, genetic predisposition, skeletal changes, acral enlargement, prognathism, kyphosis, coarse facial features, hyper glycemia, hypertension, hypogonadism, thyroid dysfunvtion, cardiomyopathy, hypertension, headaches, cognitive changes, imaging studies, oral glucose tolerance test, magnetic resonance imaging, bone density scan, cranio pharyngioma, hyper thyrroidism and radiation therapy.

Introduction:

Acromegaly is a rare endocrine disorder occured by the excessive production of growth hormone (GH) after the closure of the growth plates in adulthood. It primarily influences middle-aged adults, and its clinical features are a result of the overproduction of GH and subsequent elevation of insulin-like growth factor 1 (IGF-1).

Causes of Acromegaly

Pituitary Tumor (Adenoma):

Most common cause of Acromegaly.

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Benign tumor of the pituitary gland.

Overproduction of growth hormone (GH).

Genetic Predisposition:

In rare cases, genetic mutations can lead to excess GH production.

Familial forms of Acromegaly exist.

Gigantism:

Occurs in childhood due to GH excess before epiphyseal plate closure.

Can progress to Acromegaly if untreated.

Non-Pituitary Tumors:

Rarely, tumors outside the pituitary gland (e.g., lung, pancreas) can produce GH-releasing hormone.

Ectopic GH Production:

Occurs when tumors elsewhere in the body produce GH independently.

Idiopathic:

In some cases, the cause remains unknown.

Acromegaly typically results from an overproduction of GH, leading to excessive growth of tissues and bones in the body.

Clinical Features:

Skeletal Changes:

Gigantism:

In cases where the condition develops before the growth plates close, individuals may experience abnormal growth in height, known as gigantism.

Acral Enlargement:

Most characteristic feature; hands and feet grow larger with thickening of fingers and toes.

Prognathism:

Overgrowth of the jaw, leading to a prominent jawline.

Kyphosis:

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Abnormal curvature of the spine, often seen in long-standing cases.

Soft Tissue and Facial Changes:

Coarse Facial Features:

Thickened lips, enlarged nose, and widened spacing between teeth.

Increased Sweating:

Excessive perspiration due to increased metabolic activity.

Skin Tags and Wrinkles:

Skin abnormalities like skin tags and deepening wrinkles.

Endocrine Manifestations:

Hyperglycemia:

GH antagonizes the effects of insulin, leading to impaired glucose tolerance and diabetes mellitus.

Hypertension:

Elevated GH levels can cause increased blood pressure.

Hypogonadism:

Reduced sexual function and fertility due to hormonal imbalances.

Thyroid Dysfunction:

GH can affect thyroid hormone function.

Cardiovascular Symptoms:

Cardiomyopathy:

GH excess can lead to an enlarged heart and decreased cardiac function.

Hypertension:

Elevated blood pressure can increase the risk of cardiovascular events.

Neurological and Psychological Effects:

Headaches:

Frequent headaches due to the growth of pituitary tumors.


Visual Disturbances:

Tumors can compress the optic nerve, causing visual field defects.

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Cognitive Changes:

Some individuals may experience cognitive changes, including impaired memory and concentration.



Diagnosis:

Diagnosis of Acromegaly typically involves a combination of clinical evaluation, biochemical tests, and imaging studies.

Clinical Presentation:

Recognizing the physical signs:

Acromegaly is often characterized by gradual and progressive enlargement of body tissues, such as hands, feet, and facial features.

Common symptoms:

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Patients may experience symptoms like joint pain, fatigue, headaches, and changes in vision due to tumor compression on the optic nerve.

Biochemical Testing:

Insulin-like Growth Factor 1 (IGF-1):

Elevated levels of IGF-1 in the blood are a key indicator of acromegaly. It is a more reliable marker than growth hormone (GH) because GH levels can fluctuate throughout the day.

Oral Glucose Tolerance Test (OGTT):

In acromegaly, GH levels do not suppress properly during an OGTT, helping to confirm the diagnosis.

Imaging Studies:

Magnetic Resonance Imaging (MRI):

An MRI of the brain is used to locate and visualize the pituitary tumor responsible for excess GH production.

Computed Tomography (CT) Scan: Sometimes used if an MRI is contraindicated or inconclusive.

Other Diagnostic Tools:

Visual Field Testing:

To assess potential damage to the optic nerve due to tumor compression.

Bone Density Scan:

To evaluate bone health, as acromegaly can lead to increased bone density.

Differential Diagnosis:

It's important to rule out other conditions that may cause similar symptoms, such as gigantism (occurring in childhood) and other pituitary disorders.

Secondary Causes of GH Excess

Pituitary Adenoma-Related Conditions:

Prolactinoma: Elevated prolactin levels, galactorrhea, and menstrual irregularities

Cushing's Disease: Excess cortisol production, leading to weight gain, moon face, and hypertension

Non-functioning Pituitary Adenoma: No hormonal hypersecretion, but mass effect symptoms like headaches and visual disturbances

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Extrapituitary Tumors:

Ectopic GH-secreting tumors (e.g., lung, pancreas): GH excess without pituitary involvement

Other Hypothalamic-Pituitary Disorders:

Hypothalamic hamartoma: Disruption of hypothalamic function can affect GH regulation

Craniopharyngioma: Tumor near the pituitary/hypothalamus can cause hormonal imbalances

Non-Tumoral Conditions

Physiologic Variants:

Gigantism:

Excess GH secretion in childhood, leading to abnormal growth

Endocrine Disorders:

Hyperthyroidism:

Excess thyroid hormone can mimic some symptoms of acromegaly

Insulin resistance and metabolic syndrome: May lead to acromegaly-like features such as acanthosis nigricans.

Genetic Syndromes:

Carney Complex: Multiple endocrine neoplasias and cardiac myxomas

McCune-Albright Syndrome: Bone lesions, endocrine abnormalities

Multiple Endocrine Neoplasia Type 1 (MEN1): Pituitary adenomas and parathyroid tumors

Drug-Induced or latrogenic Causes:

Administration of GH or insulin-like growth factor-1 (IGF-1) for therapeutic purposes

Miscellaneous Causes:

Idiopathic hypersecretion of GH without identifiable cause

Endocrinology Consultation:

A specialist in endocrinology plays a crucial role in confirming the diagnosis, interpreting test results, and determining the appropriate treatment plan.

Multidisciplinary Care

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Acromegaly management often involves a team of healthcare providers, including endocrinologists, neurosurgeons, and radiologists, to provide comprehensive care.

Remember that early diagnosis and appropriate management are essential for improving the quality of life and preventing complications in individuals with acromegaly.

Treatment:

Medical Treatment:

Somatostatin Analogs: These drugs, such as octreotide and lanreotide, are often the first-line treatment to reduce growth hormone (GH) secretion.

Dopamine Agonists: Cabergoline may be used in some cases to lower GH levels.

Growth Hormone Receptor Antagonists: Pegvisomant is an option to block the effects of GH.

Combination Therapy: Sometimes, a combination of these medications is required for effective control.

Surgery (Transsphenoidal Surgery):

Removal of Tumor: Surgical removal of the tumor causing acromegaly can be curative if the entire tumor is successfully removed.

Partial Tumor Removal: In cases where complete removal is not possible, debulking surgery may be performed to reduce tumor size.

Radiation Therapy:

External Beam Radiation: Used when surgery and medications are not effective or as an adjunct therapy.

Stereotactic Radiosurgery: Precise radiation focused on the tumor.

Monitoring and Follow-Up:

Regular monitoring of GH and IGF-1 levels to assess treatment effectiveness.

Imaging to track tumor size and progression.

Management of Associated Symptoms:

Addressing comorbidities such as hypertension, diabetes, and cardiovascular issues.

Managing physical changes and complications like joint pain or sleep apnea.

Long-Term Care:

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Lifelong treatment and monitoring may be necessary even after successful surgery or medical therapy.

It's essential to note that the choice of treatment depends on individual factors, including the tumor's size and location, overall health, and the patient's preferences. Treatment plans are typically developed in collaboration with endocrinologists and neurosurgeons.

Conclusion:

Acromegaly is a complex endocrine disorder characterized by the excessive production of GH, resulting in a range of clinical manifestations affecting multiple organ systems. Early diagnosis and appropriate treatment are essential to prevent complications and improve the quality of life for individuals with this condition.

References:

1. Drewes AM, Arlien-Søborg MC, Lunde Jørgensen JO, Jensen MP. [Acromegaly and symptoms of the motor apparatus]. Ugeskr Laeger. 2018 Nov 12;180(46) [PubMed]

2. Pazarlı AC, Köseoğlu Hİ, Kutlutürk F, Gökçe E. Association of Acromegaly and Central Sleep Apnea Syndrome. Turk Thorac J. 2019 Apr;20(2):157-159. [PMC free article] [PubMed]

3. Postma MR, Wolters TLC, van den Berg G, van Herwaarden AE, Muller Kobold AC, Sluiter WJ, Wagenmakers MA, van den Bergh ACM, Wolffenbuttel BHR, Hermus ARMM, Netea-Maier RT, van Beek AP. Postoperative use of somatostatin analogs and mortality in patients with acromegaly. Eur J Endocrinol. 2019 Jan 01;180(1):1-9. [PubMed]

4. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017 Feb;20(1):22-32. [PubMed]

5. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987 Dec 10-16;330(6148):566-8. [PubMed]

3. Bogusławska A, Korbonits M. Genetics of Acromegaly and Gigantism. J Clin Med. 2021 Mar 29;10(7) [PMC free article] [PubMed]

7. Melmed S. Acromegaly. N Engl J Med. 1990 Apr 05;322(14):966-77. [PubMed]

8. Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Incidence of Benign and Malignant Tumors in Patients With Acromegaly Is Increased: A Nationwide Population-based Study. J Clin Endocrinol Metab. 2021 Nov 19;106(12):3487-3496. [PubMed]

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

9. Matyjaszek-Matuszek B, Obel E, Lewicki M, Kowalczyk-Bołtuć J, Smoleń A. Prevalence of neoplasms in patients with acromegaly - the need for a national registry. Ann Agric Environ Med. 2018 Sep 25;25(3):559-561. [PubMed]

10. Sharma AN, Tan M, Amsterdam EA, Singh GD. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management. Clin Cardiol. 2018 Mar;41(3):419-425. [PMC free article] [PubMed]

11. Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, Ferraù F, Gianfrilli D, Cozzolino A, Cristina De Martino M, Gatto F, Barone-Adesi F, Cannavò S, Trifirò G. Global epidemiology of acromegaly: a systematic review and metaanalysis. Eur J Endocrinol. 2021 Jul 01;185(2):251-263. [PubMed]

12. Preo G, De Stefani A, Dassie F, Wennberg A, Vettor R, Maffei P, Gracco A, Bruno G. The role of the dentist and orthodontist in recognizing oro-facial manifestations of acromegaly: a questionnaire-based study. Pituitary. 2022 Feb;25(1):159-166. [PMC free article] [PubMed]

13. Iuliano SL, Laws ER. Recognizing the clinical manifestations of acromegaly: case studies. J Am Assoc Nurse Pract. 2014 Mar;26(3):136-42. [PubMed]

14. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008 Jun 25;3:17. [PMC free article] [PubMed]

15. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA., Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. [PubMed]

16. Akirov A, Masri-Iraqi H, Dotan I, Shimon I. The Biochemical Diagnosis of Acromegaly. J Clin Med. 2021 Mar 09;10(5) [PMC free article] [PubMed]

17. Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb;24(1):1-13. [PMC free article] [PubMed]

18. Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmüller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf). 1997 May;46(5):531-7. [PubMed]

19. Irie M, Tsushima T. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab. 1972 Jul;35(1):97-100. [PubMed]

20. Zahr R, Fleseriu M. Updates in Diagnosis and Treatment of Acromegaly. Eur Endocrinol. 2018 Sep;14(2):57-61. [PMC free article] [PubMed]

21. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK., AACE Acromegaly Task Force. American Association of Clinical Endocrinologists

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary. Endocr Pract. 2011 Jul-Aug;17(4):636-46. [PubMed]

22. Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S. International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. J Clin Endocrinol Metab. 2021 Nov 19;106(12):3555-3568. [PubMed]

23. Wildemberg LE, da Silva Camacho AH, Miranda RL, Elias PCL, de Castro Musolino NR, Nazato D, Jallad R, Huayllas MKP, Mota JIS, Almeida T, Portes E, Ribeiro-Oliveira A, Vilar L, Boguszewski CL, Winter Tavares AB, Nunes-Nogueira VS, Mazzuco TL, Rech CGSL, Marques NV, Chimelli L, Czepielewski M, Bronstein MD, Abucham J, de Castro M, Kasuki L, Gadelha M. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. J Clin Endocrinol Metab. 2021 Jun 16;106(7):2047-2056. [PubMed]

24. Marquez Y, Tuchman A, Zada G. Surgery and radiosurgery for acromegaly: a review of indications, operative techniques, outcomes, and complications. Int J Endocrinol. 2012;2012:386401. [PMC free article] [PubMed]

25. Chen CJ, Ironside N, Pomeraniec IJ, Chivukula S, Buell TJ, Ding D, Taylor DG, Dallapiazza RF, Lee CC, Bergsneider M. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir (Wien). 2017 Nov;159(11):2193-2207. [PMC free article] [PubMed]

26. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2005 Nov;90(11):6290-5. [PubMed]

27. Alimohamadi M, Ownagh V, Mahouzi L, Ostovar A, Abbassioun K, Amirjmshidi A. The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study. Asian J Neurosurg. 2014 Jul-Sep;9(3):130-6. [PMC free article] [PubMed]

28. Granada ML. Biochemical following-up of treated acromegaly. Limitations of the current determinations of IGF-I and perspective. Minerva Endocrinol. 2019 Jun;44(2):143-158. [PubMed]

29. Leonart LP, Borba HHL, Ferreira VL, Riveros BS, Pontarolo R. Costeffectiveness of acromegaly treatments: a systematic review. Pituitary. 2018 Dec;21(6):642-652. [PubMed]

30. Ahmad MM, Buhary BM, Al Mousawi F, Alshahrani F, Brema I, Al Dahmani KM, Beshyah SA, AlMalki MH. Management of acromegaly: an exploratory survey of physicians from the Middle East and North Africa. Hormones (Athens). 2018 Sep;17(3):373-381. [PubMed]

ISSN- 2394-5125 VOL 10, ISSUE 07, 2023

31. Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L. Second line treatment of acromegaly: Pasireotide or Pegvisomant? Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101684. [PubMed]

32. Gariani K, Meyer P, Philippe J. Implications of Somatostatin Analogues in the Treatment of Acromegaly. Eur Endocrinol. 2013 Aug;9(2):132-135. [PMC free article] [PubMed]

33. Gadelha MR, Wildemberg LE, Kasuki L. The Future of Somatostatin Receptor Ligands in Acromegaly. J Clin Endocrinol Metab. 2022 Jan 18;107(2):297-308. [PMC free article] [PubMed]

34. Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther. 2016;10:227-39. [PMC free article] [PubMed]

35. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M., Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. [PMC free article] [PubMed]